Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
NPJ Breast Cancer|September 29, 2025
Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancerJustin M Balko, Luca Licata, Xiao Qian Wang, et al.
Nature Medicine|January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.
NEJM Evidence|February 6, 2024
Long-Term Outcomes of Adjuvant Denosumab in Breast CancerMichael Gnant, Sophie Frantal, Georg Pfeiler, et al.
Annals of Surgical Oncology|October 31, 2023
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)Walter P Weber, Martin Heidinger, Stefanie Hayoz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast CancerMatteo Dugo, Chiun-Sheng Huang, Daniel Egle, et al.
Nature Cancer|January 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trialGabriel Rinnerthaler, Daniel Egle, Rupert Bartsch, et al.
The New England Journal of Medicine|July 28, 2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast CancerMichael Gnant, Florian Fitzal, Gabriel Rinnerthaler, et al.
Oncotarget|September 1, 2018
Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individualityIsmael da Silva, Rene da Costa Vieira, Carolina Stella, et al.
Breast Cancer Research and Treatment|March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
The Lancet. Oncology|January 18, 2021
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L Mayer, Amylou C Dueck, Miguel Martin, et al.
Pageof 9